MX2011007589A - Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. - Google Patents

Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.

Info

Publication number
MX2011007589A
MX2011007589A MX2011007589A MX2011007589A MX2011007589A MX 2011007589 A MX2011007589 A MX 2011007589A MX 2011007589 A MX2011007589 A MX 2011007589A MX 2011007589 A MX2011007589 A MX 2011007589A MX 2011007589 A MX2011007589 A MX 2011007589A
Authority
MX
Mexico
Prior art keywords
combination
bendamustine
antibody
cancer
treatment
Prior art date
Application number
MX2011007589A
Other languages
English (en)
Spanish (es)
Inventor
Cherry Teresa Thomas
Geoffrey Chan
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MX2011007589A publication Critical patent/MX2011007589A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2011007589A 2009-01-16 2010-01-15 Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. MX2011007589A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14521009P 2009-01-16 2009-01-16
PCT/US2010/021123 WO2010083365A1 (en) 2009-01-16 2010-01-15 Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody

Publications (1)

Publication Number Publication Date
MX2011007589A true MX2011007589A (es) 2011-08-17

Family

ID=42340093

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007589A MX2011007589A (es) 2009-01-16 2010-01-15 Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.

Country Status (13)

Country Link
US (1) US20110274697A1 (enExample)
EP (1) EP2405937A4 (enExample)
JP (1) JP2012515217A (enExample)
KR (1) KR20110111303A (enExample)
CN (1) CN102355907A (enExample)
AU (1) AU2010204666A1 (enExample)
BR (1) BRPI1006829A2 (enExample)
CA (1) CA2749151A1 (enExample)
EA (1) EA201170940A1 (enExample)
IL (1) IL213794A0 (enExample)
MX (1) MX2011007589A (enExample)
SG (1) SG172792A1 (enExample)
WO (1) WO2010083365A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
SG10201606785UA (en) * 2011-08-16 2016-10-28 Morphosys Ag Combination therapy with an anti - cd19 antibody and a nitrogen mustard
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
FR2980110A1 (fr) * 2011-09-20 2013-03-22 Lfb Biotechnologies Combinaison d'anticorps anti-cd20 et de bendamustine
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
JP2019520419A (ja) * 2016-07-13 2019-07-18 武田薬品工業株式会社 脾臓チロシンキナーゼ阻害剤と他の治療薬の併用
EP3802622A4 (en) * 2018-05-29 2021-08-18 Wuxi Biologics Ireland Limited NEW BISPECIFIC ANTI-CD3 / ANTI-CD20 ANTIBODY
CN110540593B (zh) * 2018-05-29 2022-05-17 上海药明生物技术有限公司 新型的抗cd3/抗cd20双特异性抗体
BR112021005104A2 (pt) 2018-10-16 2021-06-08 US Nano Food & Drug INC formulação de injeção intratumoral
JP2023520975A (ja) 2020-04-13 2023-05-23 ユーエス・ナノ・フード・アンド・ドラッグ・インコーポレーテッド 塩基性化学療法腫瘍内注射製剤
CA3217391A1 (en) 2020-07-27 2022-02-03 Youwei ZHU Formulation of novel bispecific anti-cd3/cd20 polypeptide complex
GB202218493D0 (en) * 2022-12-08 2023-01-25 Oncopeptides Ab Novel therapeutic combinations
WO2024179545A1 (zh) * 2023-03-01 2024-09-06 上海津曼特生物科技有限公司 包含cd20/cd47阻断双功能融合蛋白的联合用药物及其用途
WO2024263798A1 (en) * 2023-06-20 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating prostate cancer
WO2024263804A2 (en) * 2023-06-20 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating kidney cancer
WO2024263801A2 (en) * 2023-06-20 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating ovarian cancer
EP4731199A2 (en) * 2023-06-21 2026-04-29 Stanislaw R. Burzynski Compositions comprising antineoplastons and methods of treating colorectal cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100944575B1 (ko) * 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US20070098718A1 (en) * 2003-11-04 2007-05-03 Chiron Methods of therapy for b cell-related cancers
CA2627923C (en) * 2005-11-10 2016-01-12 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
EP2234641B1 (en) * 2008-01-03 2015-08-19 Genmab A/S Monoclonal antibodies against cd32b

Also Published As

Publication number Publication date
CN102355907A (zh) 2012-02-15
US20110274697A1 (en) 2011-11-10
EA201170940A1 (ru) 2012-02-28
CA2749151A1 (en) 2010-07-22
IL213794A0 (en) 2011-07-31
AU2010204666A1 (en) 2011-07-21
WO2010083365A1 (en) 2010-07-22
EP2405937A4 (en) 2012-06-20
SG172792A1 (en) 2011-08-29
KR20110111303A (ko) 2011-10-10
JP2012515217A (ja) 2012-07-05
BRPI1006829A2 (pt) 2016-10-25
EP2405937A1 (en) 2012-01-18

Similar Documents

Publication Publication Date Title
EA201170940A1 (ru) Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
MX2013012253A (es) Conjugados novedosos de aglutinante-farmaco (adc) y su uso.
NZ720736A (en) Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
NZ719520A (en) Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
NZ602953A (en) Phytocannabinoids in the treatment of cancer
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
GB201111485D0 (en) Drug composition and its use in therapy
MX2011011596A (es) Perifosina y capecitabina como un tratamiento combinado para cancer.
MY173215A (en) Acetylcysteine compositions and methods of use thereof
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MX2020014208A (es) Agentes terapeuticos para administracion subcutanea optimizados.
PH12013501163A1 (en) Compositions comprising a p13k inhibitor and a mek inhibitor and their use for treating cancer
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
UA105940C2 (uk) Лікарська комбінація з теоброміном та опіатом і її використання в лікуванні кашлю
PH12012501203A1 (en) Combination of theobromine with a decongestant and its use for the treatment of cough
MX2010009697A (es) Tratamientos anticancerigenos mejorados.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
UA44395U (ru) Применение тиоцетама в качестве диуретического средства с мягким мочегонным действием в комплексном лечении
WO2012158776A3 (en) Combination therapy for treatment of cancer
TN2012000256A1 (en) Therapeutic use of protein-polymer conjugates
UA82250U (ru) Способ лечения больных с неалкогольной жировой болезнью печени
UA38340U (ru) Способ лечения женщин с патологическим прелиминарным периодом
UA69269U (ru) Способ лечения дисбактериоза у больных герпетическим стоматитом

Legal Events

Date Code Title Description
FA Abandonment or withdrawal